Theravance Biopharma’s $100.5 Million Shares Offering

Davis Polk advised the underwriters in the offering.Theravance Biopharma, Inc. executed its $100.5 million public offering of ordinary shares. Theravance Biopharma’s ordinary shares are listed on the Nasdaq Global…

This content is for members only.
Login to Read More Join Now
Martina Bellini

Author: Martina Bellini

This content is for members only.
Login to Read More Join Now